Every July 27, World Head & Neck Cancer Day — established by the International Federation of Head and Neck Oncology Societies (IFHNOS) — raises global awareness of malignancies that continue to show high incidence and mortality worldwide.

At Unilabs Switzerland, we recognise the essential role of early detection, diagnostic accuracy and multidisciplinary collaboration in improving patient outcomes.

Our commitment to diagnostic excellence is embodied by our highly specialised Head and Neck Pathology team, led by Dr M. Bongiovanni — an internationally recognised expert and co-author of several WHO Classification chapters in endocrine, head and neck pathology, and cytopathology — and by Dr C. Rivero, a recognised expert in quality-assurance practices.

Diagnostic excellence through quality assurance

Cytological-histological correlation supports continuous improvement in pathology

Diagnostic excellence relies not only on expertise but also on strong quality-assurance practices.

Cytological-histological correlation remains one of the most powerful quality-control tools in pathology, enabling continuous evaluation of diagnostic concordance and supporting ongoing performance improvement.

An integrated approach to diagnosis

Advanced ancillary studies support diagnostic, prognostic and theragnostic decisions

Our integrated diagnostic approach also includes a wide range of ancillary studies that inform diagnostic, prognostic and theragnostic decision-making.

These advanced analyses contribute to precision medicine and support personalised patient management.

Expertise, innovation and precision diagnostics

Combining specialised knowledge, advanced testing and rigorous quality processes

By combining subspecialised expertise, international scientific leadership, advanced ancillary testing and rigorous quality processes, the Unilabs Head and Neck Pathology team reaffirms its commitment to innovation, quality and diagnostic excellence in the service of patients worldwide.

Metastatic squamous cell carcinoma in a lateral cervical lymph node and its primary site, the larynx

The image featured in the original document shows a metastatic squamous cell carcinoma in a lateral cervical lymph node and its primary site in the larynx.

References

Scientific and institutional sources

1. International Federation of Head and Neck Oncology Societies (IFHNOS). World Head and Neck Cancer Week / World Head and Neck Cancer Day.

2. WHO Classification of Tumours Editorial Board. Head and Neck Tumours. WHO Classification of Tumours, 5th Edition, Volume 9. International Agency for Research on Cancer (IARC), 2024.

3. WHO Classification of Tumours Editorial Board. Endocrine and Neuroendocrine Tumours. WHO Classification of Tumours, 5th Edition, Volume 10. International Agency for Research on Cancer (IARC), 2025.

4. Ali SZ, VanderLaan PA, eds. The Bethesda System for Reporting Thyroid Cytopathology. 3rd ed. Springer, 2023.

5. Faquin WC, Rossi ED, eds. The Milan System for Reporting Salivary Gland Cytopathology. 2nd ed. Springer, 2023.

6. Rossi ED, Baloch ZW, et al. Second edition of the Milan System for Reporting Salivary Gland Cytopathology: What has changed? Cancer Cytopathology / Journal of the American Society of Cytopathology, 2024.